Ellansé is the only dermal filler to achieve instant volume and long-lasting results, using own-collagen stimulation; to deliver brighter skin with improved density, firmness and elasticity.

2011 FROST & SULLIVAN AWARD

In recognition of its pioneering Ellansé™ Family, AQTIS Medical™ was awarded the 2011 Frost & Sullivan European Technology Innovation of the Year Award in Dermal Fillers!

GENERIC NAME

Ellansé™ is a safe and clinically proven synthetic dermal filler, composed of totally smooth Polycaprolactone (PCL) microspheres, homogenously suspended in an aqueous Carboxymethyl cellulose (CMC) gel–carrier.

PRODUCT SUMMARY

Ellansé™ is a Unique Dermal Filler Family which offers a new era of safe, longer lasting and innovative solutions for beauty treatments, which are cost-effective by requiring less product for the same indications. Ellansé™ is a natural biostimulator, since is stimulates the creation of your own new collagen.

The Ellansé™ Family (S, M, L, E) addresses patients’ needs for durability, greater value and an aesthetically pleasing result with four distinctive duration formulations to choose from, lasting from one year (Ellansé™-S) up to four years (Ellansé™-E) or more, and other unique advantages combined into one.

For more information, please visit www.ellanse.com

WHAT DOES IT CONTAIN?

PCL is a well-known totally bioresorbable soft medical material, used in numerous European (CE-marked) and US Food and Drug Administration (FDA) approved commercial bioresorbable medical device applications like e.g. biodegradable sutures and orthopedic implants for several decades world-wide and has demonstrated an excellent safety profile.

CMC has been used in numerous European (CE-marked) and US Food and Drug Administration (FDA) approved commercial product applications in medical, cosmetic and pharmaceutical industries e.g. dermal fillers, oral and maxillo-facial surgery for several decades worldwide and has demonstrated an excellent safety profile.

PRODUCT RANGE

Ellansé™-S, Ellansé™-M, Ellansé™-L and Ellansé™-E differ only in their duration of performance (STAT Technology™). All other product characteristics are identical throughout the entire Ellansé™ Family.

DURATION OF EFFECT

Ellansé™ has four dermal filler options all of which deliver immediate and sustained performance, and are totally bioresorbable. The four options (Ellansé™-S, Ellansé™-M, Ellansé™-L, and Ellansé™-E) differ from each other only in their duration of performance, which ranges from 12 months up to 4 years or more (Tunable Longevity).

CLINICAL TRIALS

The safety and efficacy of the Ellansé™ dermal filler family has been studied through a two-year, prospective, randomized clinical study at Hautok clinic, Germany (December 2008 – December 2010). The study is conducted in accordance with ISO standard 14155 and the ICH GCP standard E6.

The two-year clinical study data demonstrate an excellent safety and performance profile with no adverse events reported. Further clinical studies for ongoing clinical research activities and new indications will be conducted in order to even further evidence the uniqueness and advantages of Ellansé™